Preferable Effect of Pravastatin Compared to Atorvastatin on Beta Cell Function in Japanese Early-state Type 2 Diabetes with Hypercholesterolemia

Tomoya MITA; Hirotaka WATADA; Shiho NAKAYAMA; Michiko ABE; Takeshi OGIHARA; Tomoaki SHIMIZU; Hiroshi UCHINO; Takahisa HIROSE; Ryuzo KAWAMORI

doi:10.1507/endocrj.K06-198

ORIGINALS

Preferable Effect of Pravastatin Compared to Atorvastatin on Beta Cell Function in Japanese Early-state Type 2 Diabetes with Hypercholesterolemia

Tomoya MITA, Hirotaka WATADA, Shiho NAKAYAMA, Michiko ABE, Takeshi OGIHARA, Tomoaki SHIMIZU, Hiroshi UCHINO, Takahisa HIROSE, Ryuzo KAWAMORI

Author information

Tomoya MITA
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Hirotaka WATADA
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Shiho NAKAYAMA
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Michiko ABE
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Takeshi OGIHARA
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Tomoaki SHIMIZU
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Hiroshi UCHINO
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Takahisa HIROSE
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine
Ryuzo KAWAMORI
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine

Keywords: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, Type 2 diabetes mellitus, Pancreatic beta cell, Hyperlipidemia, Clinical trial

JOURNAL FREE ACCESS

2007 Volume 54 Issue 3 Pages 441-447

DOI https://doi.org/10.1507/endocrj.K06-198

View "Advance Publication" version (April 25, 2007).

Details

Abstract

While a large numbers of clinical trials using various kinds of statins has been reported, a possible preventive effect on new onset of type 2 diabetes mellitus was shown only by the subanalysis of The West of Scotland Coronary Prevention Study (WOSCOPS) using pravastatin. The aim of this study was to investigate whether pravastatin has a preferable effect on glucose tolerance among statins. An open-label prospective cross-over trial was performed to compare the effect of pravastatin (10 mg/day) or atorvastatin (10 mg/day) in Japanese early-state type 2 diabetes mellitus with hypercholesterolemia. The analyzed study subjects were treated with pravastatin (10 mg/day, n = 12) or atorvastatin (10 mg/day, n = 12) for 12 weeks. After a 4-week-washout period, the drugs were switched and treatment was continued for another 12 weeks. Oral glucose tolerance test (OGTT) was performed to evaluate several parameters including the appropriateness of beta cell function for the individual insulin sensitivity (disposition index: product of a validated secretion parameter and sensitivity) at the end of each therapy. HbA_1c and 2 h-glucose levels during OGTT in the pravastatin treatment were significantly lower than atorvastatin treatment. Disposition index after pravastatin treatment was significantly higher than after atorvastatin treatment. In conclusion, our study suggests that pravastatin has a favorable effect on pancreatic beta cell function compared with atorvastatin.

Corresponding author

Register with J-STAGE for free!